[Apr 2, 2026] AriBio Appoints Soo Hyun Sung as Co-CEO: “Accelerating the Successful Commercialization of AR1001, the First Oral Disease-Modifying Alzheimer’s Treatment”

AriBio Appoints Soo Hyun Sung as Co-CEO: “Accelerating the Successful Commercialization of AR1001, the First Oral Disease-Modifying Alzheimer’s Treatment” Co-founder who has worked alongside CEO Jai Jun Choung for 16 years to help drive the company’s vision; veteran biopharma executive with over 25 years of leadership experience expected to lead technology commercialization and global market expansion AriBio, a company specializing in the development of therapeutics for neurodegenerative diseases, announced on April 2 that it has appointed Vice Chairman Soo Hyun Sung as Co-Chief Executive Officer, following approval by its shareholders and board of directors at meetings held on March 31. With this appointment, AriBio has established a dual leadership structure with CEO Jai Jun Choung as the company approaches several key milestones, including the completion of global Phase 3 clinical trial for its oral Alzheimer’s disease treatment candidate AR1001 and the announcement of top-line results. Under the new Co-CEO structure, Jai Jun Choung will continue to lead research and development, global clinical development, commercialization, and the advancement of scientific achievements. Soo Hyun Sung will oversee overall management, business strategy, and fundraising, with a focus on supporting the company’s sustainable growth. The company stated that this integrated leadership structure, combining scientific and management expertise, will help build a stronger and more stable foundation for future growth. Soo Hyun Sung is a Co-Founder of AriBio and a veteran executive who has demonstrated leadership in the pharmaceutical and biotechnology industries for more than 25 years. Guided by a people-centered management philosophy, she has worked alongside CEO Jai Jun Choung since the company’s founding to advance innovative treatments for neurodegenerative brain disorders. She previously served as CEO of AriBio from 2010 to 2019, and later, as Vice Chairman, led fundraising efforts and the development of the company’s research infrastructure. She also contributed to AriBio’s global market expansion and helped lay the groundwork for a stable revenue structure. In particular, she played a key role in advancing AR1001 and, based on the company’s research data in neurodegenerative brain disorders, led the development of the transcranial vibroacoustic stimulation device Herzion. She was also instrumental in successfully launching the hair-loss solution TeloAct, as well as functional cosmetics and health supplement products. AriBio said this leadership transition is expected to accelerate the successful commercialization of AR1001 and further strengthen the company’s transformation into a global innovator in drug development. Soo Hyun Sung, Co-CEO of AriBio, stated: “Having personally witnessed the profound suffering of patients living with Alzheimer’s disease, as well as the toll it takes on their families and loved ones, I carry this mission with deep empathy and responsibility. These experiences have strengthened our resolve, and we have remained steadfast in pursuing our vision. We believe that when united by a shared purpose and conviction, the dreams we pursue together can become reality. With this belief, we will continue to dedicate ourselves until we deliver the world’s first oral disease-modifying Alzheimer’s treatment to patients worldwide.” Meanwhile, as part of its strengthened efforts to enhance management and organizational accountability, AriBio is currently pursuing a merger with KOSDAQ-listed Solux, with the planned merger date set for July 10, 2026. Key Credentials of Soo Hyun Sung, Newly Appointed Co-CEO • B.A., Duksung Women’s University • M.A. in Business Administration, Dongguk University • Current: Co-Founder and Vice Chairman, AriBio • Former CEO, AriBio (2010–2019) • More than 25 years of executive leadership in the pharmaceutical and biotechnology industries, including service as CEO of Optus Pharma • Recipient of multiple honors, including the Prime Minister’s Commendation for New Drug Development, the Model SME Award from the Ministry of SMEs and Startups, the Women Entrepreneur Award, and the Seoul Outstanding Woman Entrepreneur Award

The release as fetched from its publisher. aribiogroup.com ↗